Publication details

Difúzní velkobuněčný B-lymfom

Title in English Diffuse large B-cell lymphoma
Authors

ŠÁLEK David VÁŠOVÁ Ingrid JANÍKOVÁ Andrea MICHALKA Jozef NAVRÁTIL Milan KRÁL Zdeněk MAYER Jiří

Year of publication 2011
Type Article in Periodical
Magazine / Source Postgraduální medicína
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords anthracycline; diffuse large B-cell; lymphoma; immunochemotherapy; prognosis
Description Diffuse large B-cell lymphoma (DLBCL) represents a heterogenous mixture of mature B-lymphoproliferative disorders, histologically composed of large transformed B cells with diffuse growth pattern. Overall it is the most common type of all non-Hodgkin lymphomas. According to the WHO 2008 classification, it is divided into 5 main subtypes, from which diffuse large B-cell lymphoma not otherwise specified is the most frequent one. Primary mediastinal B-cell lymphoma, formerly classified into DLBCL, is a separate entity today. The prognosis of DLBCL can be estimated with International Prognostic Index (IPI) or age-adjusted IPI in younger patients. The standard of care is a combination of anthracycline-based chemotherapy and anti-CD20 monoclonal antibody rituximab. Approximately 70% of DLBCL patients can be cured with this approach.

You are running an old browser version. We recommend updating your browser to its latest version.

More info